GB2217602A - Treatment of inflammatory disorders in humans - Google Patents
Treatment of inflammatory disorders in humans Download PDFInfo
- Publication number
- GB2217602A GB2217602A GB8908831A GB8908831A GB2217602A GB 2217602 A GB2217602 A GB 2217602A GB 8908831 A GB8908831 A GB 8908831A GB 8908831 A GB8908831 A GB 8908831A GB 2217602 A GB2217602 A GB 2217602A
- Authority
- GB
- United Kingdom
- Prior art keywords
- acid
- fatty acids
- inflammatory
- effective amount
- cyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000027866 inflammatory disease Diseases 0.000 title claims description 10
- 125000004122 cyclic group Chemical group 0.000 claims description 25
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 17
- 150000003751 zinc Chemical class 0.000 claims description 17
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 12
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 10
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 9
- 229930195729 fatty acid Natural products 0.000 claims description 9
- 239000000194 fatty acid Substances 0.000 claims description 9
- 150000004665 fatty acids Chemical class 0.000 claims description 9
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 6
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 229960004488 linolenic acid Drugs 0.000 claims description 5
- WGJJROVFWIXTPA-OALUTQOASA-N prostanoic acid Chemical compound CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(O)=O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 claims description 4
- NNOJWZIBHANBJD-OALUTQOASA-N 7-[(1S,2S)-2-octylcyclopentyl]hept-2-enoic acid Chemical compound CCCCCCCC[C@H]1CCC[C@@H]1CCCCC=CC(O)=O NNOJWZIBHANBJD-OALUTQOASA-N 0.000 claims description 3
- 150000003180 prostaglandins Chemical class 0.000 claims description 3
- SAOSKFBYQJLQOS-KTKRTIGZSA-N (9Z)-octadec-9-en-12-ynoic acid Chemical compound CCCCCC#CC\C=C/CCCCCCCC(O)=O SAOSKFBYQJLQOS-KTKRTIGZSA-N 0.000 claims 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000002085 irritant Substances 0.000 claims 3
- 230000036556 skin irritation Effects 0.000 claims 3
- CUXYLFPMQMFGPL-UHFFFAOYSA-N (9Z,11E,13E)-9,11,13-Octadecatrienoic acid Natural products CCCCC=CC=CC=CCCCCCCCC(O)=O CUXYLFPMQMFGPL-UHFFFAOYSA-N 0.000 claims 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 2
- CUXYLFPMQMFGPL-SUTYWZMXSA-N all-trans-octadeca-9,11,13-trienoic acid Chemical compound CCCC\C=C\C=C\C=C\CCCCCCCC(O)=O CUXYLFPMQMFGPL-SUTYWZMXSA-N 0.000 claims 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 2
- 229940090949 docosahexaenoic acid Drugs 0.000 claims 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 2
- 235000020778 linoleic acid Nutrition 0.000 claims 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 1
- 239000011701 zinc Substances 0.000 description 20
- 241000700159 Rattus Species 0.000 description 19
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 14
- 229910052725 zinc Inorganic materials 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 206010003246 arthritis Diseases 0.000 description 6
- LRGQZEKJTHEMOJ-UHFFFAOYSA-N propane-1,2,3-triol;zinc Chemical compound [Zn].OCC(O)CO LRGQZEKJTHEMOJ-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 241000382353 Pupa Species 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 230000002917 arthritic effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 206010017788 Gastric haemorrhage Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000036576 dermal application Effects 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003286 arthritogenic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000007882 dietary composition Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- NSTORIOUDCABGP-UHFFFAOYSA-N ethanol;prop-1-ene Chemical group CCO.CC=C NSTORIOUDCABGP-UHFFFAOYSA-N 0.000 description 1
- YZSJUQIFYHUSKU-UHFFFAOYSA-N ethanol;propane-1,2-diol Chemical compound CCO.CC(O)CO YZSJUQIFYHUSKU-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
- 229940007718 zinc hydroxide Drugs 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPI786888 | 1988-04-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB8908831D0 GB8908831D0 (en) | 1989-06-07 |
| GB2217602A true GB2217602A (en) | 1989-11-01 |
Family
ID=3773040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB8908831A Withdrawn GB2217602A (en) | 1988-04-22 | 1989-04-19 | Treatment of inflammatory disorders in humans |
Country Status (5)
| Country | Link |
|---|---|
| AU (1) | AU616502B2 (enrdf_load_stackoverflow) |
| DE (1) | DE3913194A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2630648A1 (enrdf_load_stackoverflow) |
| GB (1) | GB2217602A (enrdf_load_stackoverflow) |
| NZ (1) | NZ228862A (enrdf_load_stackoverflow) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0467564A3 (en) * | 1990-07-10 | 1992-07-08 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Treatment of inflammatory diseases with 15-keto-prostaglandin compounds |
| EP0454429A3 (en) * | 1990-04-27 | 1992-07-15 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Use of 15-dehydroxy-16-oxoprostaglandin derivatives in the treatment of allergic diseases |
| US5302617A (en) * | 1990-04-27 | 1994-04-12 | Kabushikikaisha Ueno Seiyaku Oyo Kenkyuio | Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds |
| WO1995013806A1 (en) * | 1993-11-18 | 1995-05-26 | Kappa Pharmaceuticals Limited | Compositions containing zinc linoleate for the treatment of skin disorders |
| FR2740335A1 (fr) * | 1995-10-26 | 1997-04-30 | Oreal | Utilisation de sel de lanthanide, de lithium, d'etain, de zinc, de manganese ou d'yttrium comme antagoniste de substance p |
| WO1999003463A1 (en) * | 1997-07-18 | 1999-01-28 | Kelly Patrick D | Genital lubricants with zinc to reduce irritation and allergic reactions |
| US5980477A (en) * | 1991-07-29 | 1999-11-09 | Patrick Kelly | Genital lubricants with zinc salts as anti-viral additives |
| US6423325B1 (en) | 1999-07-30 | 2002-07-23 | Conopco, Inc. | Skin care composition |
| CN1133786C (zh) * | 1994-11-08 | 2004-01-07 | 乌尔里克·赫德尔梅尔 | 泵送混凝土用的装置 |
| EP1166788A4 (en) * | 1999-03-10 | 2007-10-10 | Takata Seiyaku Kabushiki Kaish | DRUGS AGAINST JOINT DISEASES |
| WO2007066232A3 (en) * | 2005-10-07 | 2007-11-01 | Ocean Nutrition Canada Ltd | Salts of fatty acids and methods of making and using thereof |
| US8552064B2 (en) | 2002-03-26 | 2013-10-08 | Eastern Virginia Medical School | Suramin and derivatives thereof as topical microbicide and contraceptive |
| WO2019219093A3 (zh) * | 2018-05-15 | 2019-12-19 | 南京医科大学 | 亚麻酸锌的制备及其在制备抗幽门螺杆菌药物中的应用 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4042437A1 (de) * | 1990-07-18 | 1992-06-11 | Braun Melsungen Ag | Topische verwendung von (omega)-3-fettsaeuren-zubereitungen fuer verbrennungen |
| DE4022815A1 (de) * | 1990-07-18 | 1992-01-23 | Braun Melsungen Ag | Topische verwendung von (omega)-3-fettsaeuren-zubereitungen fuer hauterkrankungen |
| CN1168104A (zh) * | 1995-01-18 | 1997-12-17 | 大正制药株式会社 | 皮肤炎治疗剂 |
| FR2873295B1 (fr) * | 2004-07-26 | 2006-12-01 | Expanscience Sa Lab | Utilisation d'au moins un triene d'acide gras conjugue pour la preparation d'un medicament destine au traitement de l'inflammation |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB798655A (en) * | 1956-03-15 | 1958-07-23 | Biorex Laboratories Ltd | Improvements in or relating to therapeutic compositions |
| GB2029441A (en) * | 1978-08-21 | 1980-03-19 | Toyo Aerosol Ind Co | Powder aerosol composition |
| US4309415A (en) * | 1978-04-11 | 1982-01-05 | Verronmay Limited | Method and composition for treating inflammatory disorders |
| US4444755A (en) * | 1978-01-23 | 1984-04-24 | Efamol Limited | Treatment for skin disorders |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB943282A (en) * | 1960-10-13 | 1963-12-04 | Peter James Shannon | Hair restorer |
| FR2406775A1 (fr) * | 1977-10-19 | 1979-05-18 | Fmc Europe | Dispositif de couplage a deconnexion rapide pour applications cryogeniques |
| US4273763A (en) * | 1978-01-23 | 1981-06-16 | Efamol Limited | Pharmaceutical and dietary compositions |
| IE47777B1 (en) * | 1978-01-23 | 1984-06-13 | Efamol Ltd | Pharmaceutical and dietary composition comprising gamma-linolenic acids |
| GB2101132B (en) * | 1980-11-24 | 1985-05-15 | Reginald Morton Taylor | Pharmaceutical compound and method |
| AU556817B2 (en) * | 1982-02-03 | 1986-11-20 | Efamol Limited | Topical application of a lithium salt and dihomo-alpha- linolenic acid |
| FR2548021B1 (fr) * | 1983-06-29 | 1986-02-28 | Dick P R | Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels |
| WO1986000251A1 (en) * | 1984-06-22 | 1986-01-16 | The Taylor-Winfield Corporation | Robot welder |
| US4621075A (en) * | 1984-11-28 | 1986-11-04 | The Procter & Gamble Company | Gel-form topical antibiotic compositions |
| WO1987001281A1 (en) * | 1985-08-27 | 1987-03-12 | Glyzinc Pharmaceuticals Limited | Zinc glycerolate complex and additions for pharmaceutical applications |
-
1989
- 1989-04-14 AU AU33006/89A patent/AU616502B2/en not_active Ceased
- 1989-04-19 GB GB8908831A patent/GB2217602A/en not_active Withdrawn
- 1989-04-20 FR FR8905434A patent/FR2630648A1/fr active Pending
- 1989-04-21 DE DE3913194A patent/DE3913194A1/de not_active Withdrawn
- 1989-04-24 NZ NZ22886289A patent/NZ228862A/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB798655A (en) * | 1956-03-15 | 1958-07-23 | Biorex Laboratories Ltd | Improvements in or relating to therapeutic compositions |
| US4444755A (en) * | 1978-01-23 | 1984-04-24 | Efamol Limited | Treatment for skin disorders |
| US4309415A (en) * | 1978-04-11 | 1982-01-05 | Verronmay Limited | Method and composition for treating inflammatory disorders |
| GB2029441A (en) * | 1978-08-21 | 1980-03-19 | Toyo Aerosol Ind Co | Powder aerosol composition |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0454429A3 (en) * | 1990-04-27 | 1992-07-15 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Use of 15-dehydroxy-16-oxoprostaglandin derivatives in the treatment of allergic diseases |
| US5302617A (en) * | 1990-04-27 | 1994-04-12 | Kabushikikaisha Ueno Seiyaku Oyo Kenkyuio | Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds |
| US5346921A (en) * | 1990-07-10 | 1994-09-13 | R-Tech Ueno, Ltd. | Treatment of inflammation with 15-keto-prostaglandin compounds |
| EP0467564A3 (en) * | 1990-07-10 | 1992-07-08 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Treatment of inflammatory diseases with 15-keto-prostaglandin compounds |
| US5980477A (en) * | 1991-07-29 | 1999-11-09 | Patrick Kelly | Genital lubricants with zinc salts as anti-viral additives |
| US5792449A (en) * | 1993-11-18 | 1998-08-11 | Kappa Pharmaceuticals Limited | Compositions containing zinc linoleate for the treatment of skin disorders |
| WO1995013806A1 (en) * | 1993-11-18 | 1995-05-26 | Kappa Pharmaceuticals Limited | Compositions containing zinc linoleate for the treatment of skin disorders |
| CN1133786C (zh) * | 1994-11-08 | 2004-01-07 | 乌尔里克·赫德尔梅尔 | 泵送混凝土用的装置 |
| US5900257A (en) * | 1995-10-26 | 1999-05-04 | Societe L'oreal S.A. | Cosmetic/pharmaceutical compositions comprising lanthanide manganese, tin and/or yttrium salts as substance P antagonists |
| EP0770392A3 (fr) * | 1995-10-26 | 1997-05-07 | L'oreal | Utilisation de sel de lanthanide, d'étain de manganèse ou d'yttrium dans une composition pharmaceutique |
| FR2740335A1 (fr) * | 1995-10-26 | 1997-04-30 | Oreal | Utilisation de sel de lanthanide, de lithium, d'etain, de zinc, de manganese ou d'yttrium comme antagoniste de substance p |
| WO1999003463A1 (en) * | 1997-07-18 | 1999-01-28 | Kelly Patrick D | Genital lubricants with zinc to reduce irritation and allergic reactions |
| EP1166788A4 (en) * | 1999-03-10 | 2007-10-10 | Takata Seiyaku Kabushiki Kaish | DRUGS AGAINST JOINT DISEASES |
| CZ301736B6 (cs) * | 1999-03-10 | 2010-06-09 | Takata Seiyaku Co., Ltd. | Prostredek pro lécbu arthritidy |
| US6423325B1 (en) | 1999-07-30 | 2002-07-23 | Conopco, Inc. | Skin care composition |
| US8552064B2 (en) | 2002-03-26 | 2013-10-08 | Eastern Virginia Medical School | Suramin and derivatives thereof as topical microbicide and contraceptive |
| WO2007066232A3 (en) * | 2005-10-07 | 2007-11-01 | Ocean Nutrition Canada Ltd | Salts of fatty acids and methods of making and using thereof |
| WO2019219093A3 (zh) * | 2018-05-15 | 2019-12-19 | 南京医科大学 | 亚麻酸锌的制备及其在制备抗幽门螺杆菌药物中的应用 |
| US11203563B2 (en) | 2018-05-15 | 2021-12-21 | Nanjing Medical University | Preparation of zinc linolenate, and application of zinc linolenate in preparing anti-helicobacter pylori drug |
Also Published As
| Publication number | Publication date |
|---|---|
| DE3913194A1 (de) | 1989-11-02 |
| FR2630648A1 (enrdf_load_stackoverflow) | 1989-11-03 |
| AU3300689A (en) | 1989-10-26 |
| NZ228862A (en) | 1991-03-26 |
| GB8908831D0 (en) | 1989-06-07 |
| AU616502B2 (en) | 1991-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU616502B2 (en) | Treatment of inflammatory disorders in humans | |
| AU740443B2 (en) | Fatty acid uninterrupted by a methylene as anti-inflammatory agents in superficial tissues of mammals | |
| RO108220B1 (ro) | Preparate farmaceutice,pentru combaterea carceilor musculari si procedeu de obtinere a acestora | |
| JP7689083B2 (ja) | セチル化脂肪酸を含む組成物及びその関節炎及び炎症性関節症状の治療における使用 | |
| US20220220414A1 (en) | Method for preparing a composition comprising cetylated fatty acids | |
| EP3976023B1 (en) | Compositions comprising cetylated fatty acids for use in the treatment of gastric mucosa | |
| JPH10508287A (ja) | 多不飽和脂肪酸の安定化方法と、安定化物の治療および美容への利用 | |
| EP2708230B1 (en) | Composition for external skin use for inflammatory diseases | |
| AU1177595A (en) | Butyric ester cyto-differentiating agents | |
| EP0183322A2 (en) | Gel-form topical antibiotic compositions | |
| US4868192A (en) | Pharmaceutical compositions and methods using certain 4H-pyrano (3,2-g) quinoline compounds | |
| JP3280071B2 (ja) | 消炎鎮痛外用剤 | |
| KR950013763B1 (ko) | 레티노산 글루쿠로나이드를 포함하는 약제학적 조성물 | |
| US6376498B1 (en) | Pharmaceutical, cosmetic and/or food composition with antioxidant properties | |
| EP0354848A1 (fr) | Compositions pharmaceutiques et/ou diététiques contenant de la L-carnitine et de la L-lysine | |
| JP3215133B2 (ja) | 消炎鎮痛外用剤 | |
| JP3231079B2 (ja) | 消炎鎮痛外用剤 | |
| JP3208719B2 (ja) | 消炎鎮痛外用剤 | |
| PL200231B1 (pl) | Środek farmaceutyczny i/lub kosmetyczny zawierający kwas pantotenowy i/lub jego pochodne oraz zastosowanie mieszaniny kwasu pantotenowego i/lub jego pochodnych | |
| JP3153596B2 (ja) | 消炎鎮痛外用剤 | |
| HK40072481B (en) | Method for preparing a composition comprising cetylated fatty acids | |
| HK40072481A (en) | Method for preparing a composition comprising cetylated fatty acids | |
| EA045244B1 (ru) | Способ приготовления композиции, содержащей цетилированные жирные кислоты | |
| FR2594334A1 (fr) | Composition pharmaceutique injectable a base d'amoxicilline | |
| JPH0220612B2 (enrdf_load_stackoverflow) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |